MedicaidPrior AuthHigh impact
Pembrolizumab products (Keytruda, Keytruda Qlex)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Jul 1, 2026
We identified it
Aug 8, 2026
Summary
Humana Louisiana Medicaid has issued a new Prior Authorization policy effective July 1, 2026 for Pembrolizumab products (Keytruda IV powder, Keytruda IV solution, and Keytruda Qlex subcutaneous solution) covering 26 cancer indications. All pembrolizumab prescriptions for these conditions now require prior authorization approval before dispensing, with specific clinical criteria and exclusions that must be documented by providers.
Action Required
By July 1, 2026: Billing team must implement prior authorization workflow for all Keytruda/Keytruda Qlex claims submitted to Humana Louisiana Medicaid. (1) Update billing software to flag all J9271 and J9272 claims requiring prior auth submission before claim processing. (2) Create prior auth checklist for oncology providers documenting: diagnosis match to listed indications, treatment regimen (monotherapy vs. combination therapy), biomarker results when required (CPS, MSI-H, dMMR, TMB-H status), and confirmation of no prior anti-PD-1/PD-L1 progression. (3) Establish internal tracking system for prior auth requests with 6-month renewal reminders for ongoing treatment. (4) Notify all prescribing oncologists of new requirements and required documentation. (5) Train front-desk and billing staff on rejection protocols—claims submitted without prior authorization approval will be denied by Humana. (6) Establish expedited appeal process for urgent cases requiring rapid approval within 72 hours. Compliance is critical as non-compliance will result in claim denials and potential member out-of-pocket liability.